Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias.

The frontotemporal dementias (FTDs) are a heterogeneous group of neurodegenerative disorders that are characterized clinically by dementia, personality changes, language impairment, and occasionally extrapyramidal movement disorders. Historically, the diagnosis and classification of FTDs has been fraught with difficulties, especially with regard to establishing a consensus on the neuropathologic diagnosis. Recently, an international group of scientists participated in a consensus conference to develop such neuropathologic criteria. They recommended a diagnostic classification scheme that incorporated a biochemical analysis of the insoluble tau isoform composition, as well as ubiquitin immunohistochemistry. The use and reliability of this classification system has yet to be examined. In this study, we evaluated 21 cases of FTD. Using traditional histochemical stains and tau protein and ubiquitin immunohistochemistry, we separated each case into one of the following categories: classic Pick disease (PiD; n = 7), corticobasal degeneration (CBD; n = 5), dementia lacking distinctive histopathologic features (DLDH; n = 4), progressive supranuclear palsy (PSP; n = 2), frontotemporal lobar degeneration with motor neuron disease or motor neuron disease-type inclusions (FTLD-MND/MNI; n = 2), and neurofibrillary tangle dementia (NFTD; n = 1). Additionally, we independently categorized each case by the insoluble tau isoform pattern, including 3R (n = 5), 4R (n = 7), 3R/4R (n = 3), and no insoluble tau (n = 6). As suggested by the proposed diagnostic scheme, we found that the insoluble tau isoform patterns correlated strongly with the independently derived histopathologic diagnoses (p < 0.001). The data show that cases containing predominantly 3R tau were classic PiD (100%). Cases with predominantly 4R tau were either CBD (71%) or PSP (29%). Cases with both 3R and 4R tau were either a combination of PiD and Alzheimer disease (67%) or NFTD (33%). Finally, cases with no insoluble tau were either DLDH (67%) or FTLD-MND/MNI (33%). To further characterize these cases, we also performed quantitative Western blots for soluble tau, APOE genotyping, and, in selected cases, tau gene sequencing. We show that soluble tau is reduced in DLDH and FTLD-MND/MNI and that APOE4 is overrepresented in PiD and DLDH. We also identified a new family with the R406W mutation and pathology consistent with NFTD. This study validates the recently proposed diagnostic criteria and forms a framework for further refinement of this classification scheme.

[1]  E. Cochran,et al.  Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders , 2004 .

[2]  D. Mann,et al.  Tau haplotype frequency in frontotemporal lobar degeneration and amyotrophic lateral sclerosis , 2003, Experimental Neurology.

[3]  R. Martins,et al.  Mutations in the tau gene that cause an increase in three repeat tau and frontotemporal dementia. , 2003, Brain : a journal of neurology.

[4]  J. Trojanowski,et al.  Selective reduction of soluble Tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study , 2003, Acta Neuropathologica.

[5]  M. Spillantini,et al.  Tau gene mutations: dissecting the pathogenesis of FTDP-17. , 2002, Trends in molecular medicine.

[6]  A. Probst,et al.  Frontotemporal lobar degeneration – tau as a pied piper? , 2002, Neurogenetics.

[7]  K. Heilman,et al.  Relative Frequencies of Alzheimer Disease, Lewy Body, Vascular and Frontotemporal Dementia, and Hippocampal Sclerosis in the State of Florida Brain Bank , 2002, Alzheimer disease and associated disorders.

[8]  J. Trojanowski,et al.  Biochemical Analysis of τ Proteins in Argyrophilic Grain Disease, Alzheimer's Disease, and Pick's Disease: A Comparative Study , 2002 .

[9]  G. Schellenberg,et al.  tau Exon 10 Expression Involves a Bipartite Intron 10 Regulatory Sequence and Weak 5′ and 3′ Splice Sites* , 2002, The Journal of Biological Chemistry.

[10]  B. Dubois,et al.  Apolipoprotein E gene in frontotemporal dementia: an association study and meta-analysis , 2002, European Journal of Human Genetics.

[11]  Murray Grossman,et al.  Signature tau neuropathology in gray and white matter of corticobasal degeneration. , 2002, The American journal of pathology.

[12]  Hans Förstl,et al.  Apolipoprotein E polymorphism in German patients with frontotemporal degeneration , 2002, Journal of neurology, neurosurgery, and psychiatry.

[13]  E. Nanba,et al.  Early-onset, rapidly progressive familial tauopathy with R406W mutation , 2002, Neurology.

[14]  B Miller,et al.  Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. , 2001, Archives of neurology.

[15]  J. Hardy,et al.  Relationship of the extended tau haplotype to tau biochemistry and neuropathology in progressive supranuclear palsy , 2001, Annals of neurology.

[16]  Takashi Asada,et al.  Genetic Analysis in Patients with Familial and Sporadic Frontotemporal Dementia: Two Tau Mutations in Only Familial Cases and No Association with Apolipoprotein ε4 , 2001, Dementia and Geriatric Cognitive Disorders.

[17]  J. Trojanowski,et al.  Frontotemporal dementia and tauopathy , 2001, Current neurology and neuroscience reports.

[18]  T. Tabira,et al.  Familial frontotemporal dementia and parkinsonism with a novel mutation at an intron 10+11‐splice site in the tau gene , 2001, Annals of neurology.

[19]  J. Hodges.  Frontotemporal dementia (Pick’s disease): Clinical features and assessment , 2001, Neurology.

[20]  M. Hutton.  Missense and splice site mutations in tau associated with FTDP-17: Multiple pathogenic mechanisms , 2001, Neurology.

[21]  K. Blennow,et al.  Clinic-Based Cases with Frontotemporal Dementia Show Increased Cerebrospinal Fluid Tau and High Apolipoprotein E ε4 Frequency, but No Tau Gene Mutations , 2001, Experimental Neurology.

[22]  J. Trojanowski,et al.  Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia , 2001, Annals of neurology.

[23]  T. Beach,et al.  Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick's disease, corticobasal degeneration and progressive supranuclear palsy , 2001, Acta Neuropathologica.

[24]  M. Hutton,et al.  Phenotypic correlations in FTDP-17 , 2001, Neurobiology of Aging.

[25]  Z. Janka,et al.  Apolipoprotein E polymorphism in Pick’s disease and in Huntington’s disease , 2000, Neurobiology of Aging.

[26]  D. Neary,et al.  Apolipoprotein E ϵ4 Allele Has No Effect on Age at Onset or Duration of Disease in Cases of Frontotemporal Dementia with Pick- or Microvacuolar-Type Histology , 2000, Experimental Neurology.

[27]  M. Hutton.  Molecular genetics of chromosome 17 tauopathies , 2000, Neurobiology of Aging.

[28]  G. Schellenberg,et al.  A novel mutation at position +12 in the intron following Exon 10 of the tau gene in familial frontotemporal dementia (FTD‐Kumamoto) , 2000, Annals of neurology.

[29]  A. Delacourte,et al.  Comparative Biochemistry of Tau in Progressive Supranuclear Palsy, Corticobasal Degeneration, FTDP‐17 and Pick's Disease , 1999, Brain pathology.

[30]  D. Dickson,et al.  Tau gene mutation in familial progressive subcortical gliosis , 1999, Nature Medicine.

[31]  D. Geschwind,et al.  The apolipoprotein E ε4 allele is not a significant risk factor for frontotemporal dementia , 1998 .

[32]  P. Trouillas,et al.  Spontaneous Intracerebral Hemorrhage Revealing Addison’s Disease , 1998, Cerebrovascular Diseases.

[33]  A Klug,et al.  Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[35]  G. Schellenberg,et al.  Tau is a candidate gene for chromosome 17 frontotemporal dementia , 1998, Annals of neurology.

[36]  J. Hardy,et al.  ApoE genotype is a risk factor in nonpresenilin early-onset Alzheimer's disease families. , 1998, American journal of medical genetics.

[37]  M. L. Schmidt,et al.  Autosomal dominant dementia with widespread neurofibrillary tangles , 1997, Annals of neurology.

[38]  M. Abrahamson,et al.  Apolipoprotein-E genotyping in Alzheimer's disease and frontotemporal dementia. , 1997, Dementia and geriatric cognitive disorders.

[39]  B. Crain,et al.  Rapid brain autopsy. The Joseph and Kathleen Bryan Alzheimer's Disease Research Center experience. , 1997, Archives of pathology & laboratory medicine.

[40]  K. Blennow,et al.  The apolipoprotein E ϵ4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of disease , 1997, Neuroscience Letters.

[41]  M. Pericak-Vance,et al.  Linkage of frontotemporal dementia to chromosome 17: clinical and neuropathological characterization of phenotype. , 1996, American journal of human genetics.

[42]  P. Hof,et al.  Specific Pathological Tau Protein Variants Characterize Pick's Disease , 1996, Journal of neuropathology and experimental neurology.

[43]  A. Pick,et al.  Senile Hirnatrophie als Grundlage von Herderscheinungen , 1995 .

[44]  John Hardy,et al.  Single-day apolipoprotein E genotyping , 1994, Journal of Neuroscience Methods.

[45]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[46]  A. Delacourte,et al.  Abnormal Tau proteins in progressive supranuclear palsy , 1991, Acta Neuropathologica.

[47]  A. Delacourte,et al.  Abnormal tau species are produced during Alzheimer's disease neurodegenerating process , 1989, FEBS letters.

[48]  K. Onari,et al.  Anatomische beiträge zur lehre von der pickschen umschriebenen gro\hirnrinden-atrophie („picksche krankheit“) , 1926 .

[49]  E. Altman.  Über die umschriebene Gehirnatrophie des späteren Alters , 1923 .

[50]  A. Alzheimer.  über eigenartige Krankheitsfälle des späteren Alters , 1911 .

[51]  J. Trojanowski,et al.  Biochemical analysis of tau proteins in argyrophilic grain disease, Alzheimer's disease, and Pick's disease : a comparative study. , 2002, The American journal of pathology.

[52]  J. Trojanowski,et al.  Neurodegenerative tauopathies. , 2001, Annual review of neuroscience.

[53]  D. Geschwind,et al.  The apolipoprotein E epsilon4 allele is not a significant risk factor for frontotemporal dementia. , 1998, Annals of neurology.

[54]  M A Pericak-Vance,et al.  Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. , 1993, Neurology.

[55]  R. Tissot,et al.  Pick's disease. Histological and clinical correlations. , 1974, European neurology.

[56]  J. Constantinidis,et al.  Pick’s Disease , 1974 .

[57]  A. Pick.  Zur Symptomatologie der linksseitigen Schläfenlappenatrophie. , 1904 .

[58]  A. Pick,et al.  Uber die Beziehungen der senilen Hirnatrophie zur Aphasie , 1892 .